Mr. Don Cilla reports

APPILI THERAPEUTICS ANNOUNCES PROPOSED NON-BROKERED PRIVATE PLACEMENT

Appili Therapeutics Inc. has arranged a non-brokered private placement of up to approximately 30 million units of the company at a price of 2.5 cents per unit for aggregate gross proceeds of up to approximately $750,000.

Each unit, priced at 2.5 cents, will consist of one Class A common share of the company and one-half of one common share purchase warrant of the company. Subject to receipt of shareholder approval, each warrant will entitle the holder to acquire one common share at a price of five cents per common share for 36 months from the closing date of the private placement. Pursuant to the requirements of the Toronto Stock Exchange, the warrants will not be exercisable until such time as the company obtains requisite shareholder approval (which for certainty will exclude the votes of holders of warrants), such approval to be sought no later than the next annual general meeting of the company's shareholders. If the warrants do not receive shareholder approval, the warrants will not be exercisable.

The company intends to use the net proceeds from the private placement primarily for working capital purposes and to finance the development of certain product candidates of the company.

The private placement is subject to certain closing conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX.

The company anticipates closing the private placement in November, 2025.

Certain finders will be entitled to a cash fee equal to 8.0 per cent of the gross proceeds raised in the private placement and broker warrants to purchase common shares equal to 8.0 per cent of the number of units issued under the private placement. Subject to receipt of shareholder approval, each broker warrant will entitle the holder to acquire one common share at a price of not less than 2.834 cents per common share for 24 months from the closing date. Pursuant to the requirements of the TSX, the broker warrants will not be exercisable until such time as the company obtains requisite shareholder approval (which for certainty will exclude the votes of holders of broker warrants), such approval to be sought no later than the next annual general meeting of the company's shareholders. If the broker warrants do not receive shareholder approval, the broker warrants will not be exercisable.

All securities issued pursuant to the private placement will be subject to a statutory hold period of four months and one day from the date of issuance.

About Appili Therapeutics Inc.

Appili Therapeutics is a biopharmaceutical company that is purposefully built, portfolio driven and people focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The company is currently advancing a diverse range of anti-infectives, including a U.S. Food and Drug Administration-approved ready-made suspension of metronidazole for the treatment of anti-microbial resistant infections, a vaccine candidate to prevent tularemia, a serious biological weapon threat and a topical anti-parasitic for the treatment of cutaneous leishmaniasis, a disfiguring disease. Led by a proven management team, Appili is at the centre of the global fight against infection.

We seek Safe Harbor.